Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will It Be a Boost For Pharma Stocks Too?
Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will It Be a Boost For Pharma Stocks Too?
In September, Biden unveiled a $240 million investment to combat cancer, augmenting the administration's "Cancer Moonshot", an initiative with an array of new health resources.
9月,拜登宣佈了一項2.4億美元的抗癌投資,以增強政府的 “Cancer Moonshot” 計劃,該計劃提供了一系列新的醫療資源。
The funding, allocated through the recently established Advanced Research Projects Agency for Health (ARPA-H) will support researchers engaged in projects spanning cancer prevention, detection, treatment, and survival. These initiatives include endeavors to enhance early cancer detection, improve the visualization of cancer cells during surgery, and develop devices capable of delivering treatments directly to cancer cells for more effective tumor treatment.
這筆資金由最近成立的衛生高級研究項目局(ARPA-H)分配,將支持參與癌症預防、檢測、治療和生存等項目的研究人員。這些舉措包括努力加強癌症的早期檢測,改善手術期間癌細胞的可視化,以及開發能夠直接向癌細胞提供治療以實現更有效的腫瘤治療的設備。
Reflecting on the broad impact of the fight against cancer, Biden remarked, "Almost everywhere we go, whether it's meeting with folks at local events or meeting with world leaders, beating cancer brings people together, no matter where you are."
在回顧抗擊癌症的廣泛影響時,拜登說:“無論我們走到哪裏,無論是在當地活動中與人們會面還是與世界領導人會面,戰勝癌症都會使人們團結起來,無論你身在何處。”
Biden revamped the Cancer Moonshot program, which started when he was in office as Vice President, last year with the goal of cutting the cancer death rate in half by 2047.
拜登去年修改了他在擔任副總統時啓動的Cancer Moonshot計劃,目標是到2047年將癌症死亡率降低一半。
Additional Investment
額外投資
The influx of money will drive innovations that will benefit not just those the treatments save, but the companies that develop and sell them too. Companies with promising treatments already in the pipeline may get the push they need to get life-saving drugs to market.
資金的湧入將推動創新,這些創新不僅將使療法所拯救的人受益,還會使開發和銷售這些療法的公司受益。已經在研發有前景的治療方法的公司可能會獲得必要的推動力,將救生藥物推向市場。
Investors can choose to back individual stocks or go with a thematic ETF like the Tema Oncology ETF (NASDAQ:CANC), which allows investors to help drive cancer research and benefit from the innovations it provides. The fund believes that oncology is at an inflection point and a burst of progress is on the horizon; progress that may be, in part, driven by the administration's cancer moonshot funding.
投資者可以選擇支持個股,也可以選擇主題ETF,例如Tema Oncology ETF(納斯達克股票代碼:CANC),這使投資者能夠幫助推動癌症研究並從其提供的創新中受益。該基金認爲,腫瘤學正處於轉折點,即將取得突破性進展;這些進展可能部分是由政府的癌症登月資金推動的。
CANC is new, launched this summer, and has assets under management south of $20 million and an expense ratio of .75%. It's up more than 6% over the trailing month.
CANC是新成立的,於今年夏天推出,管理的資產超過2000萬美元,支出比率爲0.75%。在過去的一個月中,它上漲了6%以上。